Professor Qide Han
President of PUHSC
Qide Han, Professor of pathophysiology, is the President of Peking University Health Science Center. He is Vice-Chairman of the National Committee of Chinese People's Political Consultative Conference, Chairman of the Central Committee of Jiusan (September 3rd) Society, Chairman of China Association for Science and Technology, Director of Peking University Bio-medical Cross Discipline Research Center. Professor Han is an academician of Chinese Academy of Sciences, and academician of the Third World Academy of Sciences.
Professor Han received his Bachelor’s Degree in clinical medicine from First Medical College of Shanghai in 1968, and a Master’s Degree in Pathophysiology from Xi’An Medical College in 1982. He was a visiting Scholar in Emory University, USA from 1985 to 1987.
Professor Han’s major research area is in molecular pharmacology and cardiovascular sciences. He made great achievement in the area of α1-AR subtypes research. In 1987, he discovered that α1-AR has two subtypes; he then conducted systematic research on the distribution and function of cardiovascular system and the pathophysiology changes of α1-AR subtypes. More recently, he has been focused on interdisciplinary research, and started the study of single – molecule transport and its biological significance, as well as the network control and integrity of gene expressing and signaling of the cardiac adrenoceptor subtypes. Prof. Han has published more than 200 academic papers, and the papers have been cited for over 1700 times by SCI searched journals.
Professor Han has received many awards, including First Prize of China’s State Education Commission Award for Science and Technology Advancement in 1992, Third Prize of China’s Ministry of Health Award for Science and Technology Advancement in 1993, Third Prize of China’s National Natural Science Award in 1994, First Prize of China’s State Education Commission Award for Science and Technology Advancement in 1995, Heliang - Heli Award for Advance in Science and Technology in 1998, First Prize of China’s University Natural Science Award in 2000, title of “Excellent Returned Overseas Chinese Scholar” awarded by China’s Ministry of Health in 1990, title of “Returned Overseas Chinese Scholar with Outstanding Contribution” awarded by China’s Ministry of Personnel and State Education Commission in 1991, title of “Young and Middle-Aged Experts with Outstanding Contribution” awarded by China’s Ministry of Personnel in 1994. Professor Han has been the doctoral supervisor since 1993, and has cultivated 33 doctors, 8 masters, and trained 8 post-doctors.
Professor Han was the Vice Chairman for the 10th and 11th Standing Committee of National People’s Congress, Director for the Western Returned Scholars Association Chinese Overseas-Educated Scholars Association. He was also the Executive Vice President of Peking University and Dean of its Graduate School, the Vice President of Beijing Medical University and Dean of its Graduate School, and the Director of Department of Cardiovascular Diseases in Beijing Medical University.
Professor Yang Ke
Executive Vice-president of Peking University and PUHSC
Professor Yang Ke received her clinical training at Beijing Jishuitan Hospital from 1976 to 1979 and obtained her Master’s degree in cell biology in 1982. After that, she worked in the Laboratory of Genetics at Beijing Cancer Hospital & Beijing Institute for Cancer Research (renamed Peking University Cancer Hospital & Institute in 2000). From 1985 to 1988, she went to the Laboratory of Human Carcinogenesis of National Cancer Institute of National Institute of Health as a doctoral visiting fellow. She became the Vice President of Beijing Cancer Hospital & Beijing Institute for Cancer Research (renamed Peking University Cancer Hospital & Institute in 2000) in 1996 and was promoted to Vice President of PUHSC in 2001. Since 2004, she serves as the Executive Vice President of PKU and PUHSC. Meanwhile, she is also member or leader of many scientific-professional societies, boards and committees for cancer research, health professional education and health system reforms at home and abroad.
As the Executive Vice President of PKU for health sciences, Professor Ke is in charge of the overall administration of PUHSC. She leads the coordination and reformation of medical education, scientific research and medical services. Professor Ke is a scholar-leader who attaches great importance to investigation and research, thinking, and learning new knowledge in her management work. By integrating international perspective and democratic work-style as well as inclusive thoughts, she has established a high prestige among faculties and students and has effectively coordinated the relationship between PUHSC and PKU, which contributes to the smooth operation of routine work and the steady implementation of reform in PUHSC.
Professor Ke’s devotion to health professional education for a new century and her notable achievements in this area has made her an outstanding educator. Exceptional passion for students makes her a most popular educator among students at PKU. She has been a passionate leader in medical education reform. She has a good understanding of medical technology advance, health system problems, determinants of health, and characteristics of contemporary youth. All of those plus her leadership position enable her to strengthen correct education ideas, adjust and build bridges across different disciplines of health sciences and harness the expertise and interdisciplinary power of PUHSC and its affiliated hospitals for teaching and scientific research, eventually promoting health system reform through the path of health professional education. Professor Ke plays an important role in motivating University-affiliated hospitals to actively participate in national health system reforms. As a member of Chinese People's Political Consultative Conference (CPPCC), she has brought forward 26 proposals on health system reform and medical education at CPPCC in the past 6 years.In addition, Professor Ke is a productive researcher in cancer studies. Her major area of research is on the environmental and genetic factors of upper digestive tract malignant tumors. As the first or corresponding author, she has published over 80 papers in peer-reviewed, SCI-cited journals including Lancet, Emerging Infectious Diseases, Cancer Epidemiol Biomarkers Prev, Carcinogenesis and J Biol Chem.
Professor Weigang Fang
Vice President of PUHSC
Professor Weigang Fang is Vice President for Research and International Collaboration at PUHSC. He graduated from Beijing Medical University (BMU, which became PUHSC from April 2000), received his Bachelor’s Degree in Basic Medical Sciences in 1982 and PhD degree in Pathology/Pathophysiology in 1991. He was awarded a WHO Fellowship and was trained on signal transduction mechanisms involved in androgen-independent prostate cancer at the National Cancer Institute in the United States from 1989 to 1991. He was appointed as professor of pathology in 1995 and served as Vice Chair at the Department of Pathology, BMU from 1995 to 2000.
Now he is also the Associate Director of Peking University Cancer Research Center and leads a research team in his Molecular Pathology Laboratory. His research interest has focused, for the past 20 years, on molecular mechanisms of tumour metastasis as well as signalling mechanisms underlying prostate cancer progression. In his academic career, Dr Fang has been PIs for more than 20 peer-reviewed research projects including 8 from the Natural Science Foundation of China. He has published more than 100 research articles and reviews as well as a book on tumour invasion and metastasis as the co-chief editor.
Professor Fang started his administrative career in 1996 as Deputy Dean of Graduate School of BMU. In 2000, he was appointed as Director of Research Department in PUHSC to provide leadership and effective strategic management for research activities. During the past 7 years in his role as Vice President for Research of PUHSC, the research funding in PUHSC has been tripled, and the number of research papers published in internationally peer-reviewed SCI journals increased by 260%, keeping PUHSC as the leading medical schools in the mainland of China.He also holds academic positions including: President of Chinese Society of Tumor Metastasis Research, China Anticancer Association; Board member of China Medical Association; and President of Chinese Division, International Academy of Pathologists.
Professor Yuwu Jiang
Co-Director, Peking University Medical Genetics Center
Dr Jiang is the member of ILAE Genetics Commission, President of the Youth Committee of Chinese Association Against Epilepsy (CAAE), Executive Committee member of Chinese Neuroscience Society and President of the Youth Committee of Chinese Neuroscience Society. He is the Editorial Board member of Journal of Child Neurology, USA. He was awarded Distinguished International Academician by University of Minnesota, USA in 2010. He worked as a postdoc in the Medical School of Johns Hopkins University from August 2003 to June 2005. His Research interest is molecular and genetic mechanism of developmental brain diseases (including genetic epilepsy, mental retardation, and related neurogenetic diseases), supported by multiple grants from China National Key Research Project, National Natural Science Fund of China, etc. He has published 53 papers in international and domestic journals as the first or corresponding author.
Professor Jie Ding
Vice-President of Peking University First Hospital
Professor Jie Ding is the President of the Chinese Society of Pediatric Nephrology. Professor Ding is serving or used to serve in the International Pediatric Association (IPA) as the Standing Committee member, in the International Pediatric Nephrology Association (IPNA) as the councillor member, and the Assail Pediatric Nephrology Association (AsPNA) as the councillor member.
Professor Ding graduated from Beijing Medical College in 1982 and was trained in Pediatric Nephrology in University of Minnesota from the late 80’s to early 90’s.Professor Ding has been working as a doctor for about 30 years in the field of pediatric nephrology. Her research focuses on hereditary renal diseases, especially Alport syndrome. She has been awarded many national research grants as PI as well as a NIH R01 grant as a site-PI. She received the highest state-level scientific research award in China, the second prize of the National Scientific and Technological Progress Award. Professor Ding has an outstanding sensitivity for clinical science issues. In the outbreak of melamine-induced childhood kidney stone in China in 2008, Professor Ding, as the state-level expert on pediatric nephrology, promptly carried out a wonderful clinical study, the result of which was published on NEJM in 2009.
Professor Yangfeng Wu
Executive Associate Director, Peking University Clinical Research Institute
After receiving his undergraduate and graduate training in medicine, public health and epidemiology, Professor Wu started his career as a research fellow in the US-PRC Collaborative Study of Cardiovascular and Cardiopulmonary Epidemiology. His research focuses on prevention and control of cardiovascular disease and he has published near 200 peer-reviewed papers in both Chinese and international journals. As a cardiovascular expert, Professor Wu has made valuable contributions to reduce the impact of cardiovascular disease in China, and hence has received many awards and honours from the Chinese government and non-governmental agencies. In 2009, he founded the China International Centre for Chronic Disease Prevention in Beijing, a network of 12 Chinese and international research institutions. Through the Centre, a large project is currently under way to provide low-cost, simple interventions for blood-pressure control and stroke prevention in 120 villages from ten counties in five provinces of China.Besides his own research, Professor Wu has made great efforts to develop research platforms for high-quality clinical research in China. He is the founding Director of The George Institute for Global Health, China. He is also one of the founders of Peking University Clinical Research Institute, the first of its kind in China to provide professional technical support to clinicians in designing, implementing and analysing clinical studies.
Professor Dame Nancy Rothwell
President and Vice-Chancellor of the University of Manchester
Professor Dame Nancy Rothwell is President and Vice-Chancellor of the University of Manchester. She was elected as a Fellow of the Royal Society, the Academy of Medical Sciences and Honorary Fellow of the Royal College of Physicians. She was made made Dame Commander of the Order of the British Empire in June 2005 in recognition of her services to science.
She obtained a first class degree in Physiology, a PhD and a DSc from the University of London. In 1984, she was awarded a Royal Society Research Fellowship and was awarded a Chair in Physiology at Manchester in 1994, then a prestigious Medical Research Council Chair in 1998. She has served as president of the British Neuroscience Association, a council member of the MRC, BBSRC, the Academy of Medical Sciences and Cancer Research UK.
Dame Nancy is a member of the Royal Society Council, Vice-President of the Royal Society, Chair of the Royal Society Education Committee, President of the Society of Biology and a non-executive director of AstraZeneca. She began her research career in the field of obesity and metabolism, an area in which she rapidly acquired an international reputation. More recently, she has investigated how brain cells are damaged as a result of several different diseases, such as stroke and Alzheimer's.
Dame Nancy became President and Vice-Chancellor in July 2010, the first woman to lead The University of Manchester or either of its two predecessor institutions. She was the founding President of the Society of Biology, a non-executive Director of AstraZeneca, co-Chair of the Prime Minister’s Council for Science and Technology, a Royal Society Council Member, a Deputy Lieutenant for Greater Manchester and a member of the Greater Manchester Local Enterprise Partnership Board. She also takes a strong and active interest in public communication of science and regularly gives talks to school and the public, and contributes to television, radio and press, particularly on sensitive issues in science. In 1998, she delivered the Royal Institution Christmas Lecture, televised by the BBC.
Sir Michael Deegan
Chief Executive of Central Manchester University Hospitals NHS Trust (CMFT)
Mike Deegan has been Chief Executive of CMFT since 2001 and has led the Trust through a successful merger, upon its establishment; overseen the £520m PFI redevelopment of its Oxford Road campus; attained, in partnership with the University of Manchester, Biomedical Research Centre designation in 2008; and, managed the transition to Foundation Trust status with effect from January 2009. The FT is also the first NHS lead sponsor of a groundbreaking Academy for Health, Bioscience and Sport, opening in September 2009, with up to 720 places for 11 – 18 year old students.
Prior to his current appointment, he was Chief Executive of North Cheshire Hospitals NHS Trust and, in summer 2000, was seconded to the Department of Health as Project Director charged with developing the NHS Plan. Earlier in his career, Mike had worked for several years in the Department of Health, latterly as the Acting Director of Human Resources for the NHS.
Mike has led a range of national committees and groups for the Department of Health and the NHS Confederation; chaired the Modernisation Agency Steering Group on behalf of the National Modernisation Board; and a member of Lord Darzi’s High Quality Care For All Advisory Panel and the NIHR NHS/Biopharmaceutical Industry R&D Leadership Forum. He is also a Trustee of the Nuffield Trust.
Mike has a First Degree in Law and a Master’s Degree in Industrial Relations from the University of Warwick. He was awarded a CBE in 2002 and received a Knighthood in 2014, for services to the NHS. He has also worked widely across the public sector including roles in local government and education.
Professor Colin Sibley
Head of the Research and Innovation Division at CMFT and Professor of Child Health and Physiology, University of Manchester
Colin Sibley obtained a first class honours degree in Biochemistry and Physiology (1976) and his PhD from the University of London (1980). He worked for three years with Professor Anthony Firth as a Postdoctoral Research Assistant in the Department of Anatomy at St George's Hospital Medical School in London. In 1982, Colin became Wellcome Trust Lecturer in Child Health and Physiology at the University of Manchester and the following year was appointed to a substantive University Lectureship. He spent a year on sabbatical in 1989 as a Visiting Scientist in the Department of Pharmacology at Washington University St Louis, working with Professor Irv Boime. He became Senior Lecturer in 1990, Reader in 1994 and was appointed to a personal Chair in 1997. In 1997, Colin became a Research Division Leader in The Medical School and in 2001 was appointed Research Dean in the Faculty of Medicine, Nursing, Dentistry and Pharmacy, continuing this role as Associate Dean for Research in the Faculty of Medical and Human Sciences when the Victoria University of Manchester and UMIST merged in 2004, completing his term of office at the end of 2007.
Colin is currently Professor of Child Health and Physiology in the Maternal and Fetal Health Research Centre in the Institute of Human Development and Director of the Tommy’s Charity, Maternal and Fetal Health Research Centre (MFHRC) in Manchester. He has published over 160 peer reviewed papers, currently holds several major grants from the Medical Research Council (including PI on an MRC Programme Grant), The Wellcome Trust, Department of Health and other AMRC charities and leads his own group of around 20 researchers, as well as the 70 plus scientists and clinician-scientists, technical and clerical staff of the MFHRC. Colin has supervised more than 25 successful PhD and MD students.In 2009 Colin was appointed Head of the Research and Innovation Division at Central Manchester University Hospitals NHS Foundation Trust. In this role he is responsible for research and innovation strategy in one of the largest hospitals in the UK. This was followed by appointment as Research Director of Manchester Academic Health Science Centre in 2013.
Professor Bill Newman
Professor of Translational Genomic Medicine, Lead for Manchester Centre for Genomic Medicine, University of Manchester; and Honorary Consultant, Saint Mary’s Ho
Professor Graeme Black
Strategic Director, Manchester Centre for Genomic Medicine and Honorary Consultant in Genetics and Ophthalmology, St Mary’s Hospital
Strategic Director, Manchester Centre for Genomic Medicine, University of Manchester
Graeme qualified in Medicine from Oxford and then undertook clinical training in Ophthalmology and Medical Genetics. He is now Professor of Genetics and Ophthalmology Central Manchester and Manchester Children's University Hospitals NHS Trust. During training he undertook at DPhil with Professor Ian Craig in the Department of Biochemistry in Oxford, studying the genetics of X-linked inherited ophthalmic disease. It was this period thatenabled Graeme to develop my combined subspecialty interests. Having moved to Manchester in 1995 Graeme became a Wellcome Trust Clinician Scientist Fellow in 1997. He was awarded a Wellcome Trust Senior Research Fellowship in Clinical Science in 2002 to focus on functional analyses of recently identified genes, defining their role in normal development as well as in the disorders studied. Graeme's research interests centre on inherited disorders that are associated with visual disability and blindness, their causes and their management.